Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Share this content:
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
The following article features coverage from the 2019 Genitourinary Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

Trimodal therapy for muscle-invasive bladder cancer (MIBC) is associated with worse outcomes and higher costs compared with radical cystectomy (RC), investigators concluded during a presentation at the 2019 Genitourinary Cancers Symposium.

Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, Mohamed Danny Ray-Zack, MBBS, of the University of Texas Medical Branch at Galveston, and colleagues identified 2963 patients aged 66 years or older diagnosed with clinical stage T2-4a bladder cancer between January 1, 2002, and December 31, 2011. Of these, 728 (24.6%) patients underwent trimodal therapy and 2235 (75.4%) patients underwent RC.

Compared with the RC group, the patients who received trimodal therapy had a significant 1.50-fold increased risk of cancer-specific mortality (hazard ratio [HR], 1.50; 95% CI, 1.32-1.70) and 1.38-fold increased risk death from any cause (HR, 1.38; 95% CI, 1.25-1.53), in adjusted analyses, the investigators reported. Based on propensity score matching, RC was associated with a 1.49-fold increased risk of cancer-specific mortality (HR, 1.49; 95% CI, 1.31-1.69) and 1.55-fold increased risk of death from any cause (HR, 1.55; 95% CI, 1.32-1.83).

An analysis of total costs of treatment over 6 months showed that trimodal therapy cost a median $91,468 more than RC in the propensity score-matched cohort, Dr Ray-Zack and his colleagues reported.

“In the absence of data from randomized controlled trials, this observational study provides further evidence to suggest the superiority of radical cystectomy over trimodal therapy in patients with muscle-invasive bladder cancer,” the authors concluded.

Read more of Cancer Therapy Advisor's coverage of the 2019 Genitourinary Cancers Symposium by visiting the conference page.

Reference

  1. Ray-Zack MD, Shan Y, Kerr P, et al. Comparing radical cystectomy with trimodal therapy for patients diagnosed with bladder cancer: Critical assessment of statistical methodology and interpretation of observational data. Data presented at: 2019 Genitourinary Cancers Symposium; San Francisco, CA; February 14-16. Abstract 373.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Cancer Therapy Advisor Articles